BioMarin Pharmaceutical Inc. announced its most recent results for valoctocogene roxaparvovec at the 2017 American Society of Hemophilia event over the weekend. Valoctocogene roxaparvovec is a treatment for severe hemophilia. “We …
The risk-reward has certainly improved, yet I am not pulling the trigger yet. BioMarin (BMRN) is a much debated stock even as its stock has been trading in a relative narrow $80-100 trading range so far this year, actually trading towards …
BioMarin Pharmaceutical Inc. (BMRN) traded on unusually high volume on Feb. 06, as the stock lost 0.55% to close at $86.93. On the day, BioMarin Pharmaceutical Inc. saw 1.91 million shares trade hands on 19,801 trades. Considering …
... Pharmaceutical Inc. BMRN was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which …
Nasdaq5mon
The stock of San Rafael-based BioMarin Pharmaceutical gained more than 9 percent in value Thursday after a report that Swiss pharmaceutical giant Roche is attempting to acquire it. BioMarin’s stock, which trades on NASDAQ, closed at …
A month has gone by since the last earnings report for BioMarin Pharmaceutical Inc. BMRN. Shares have lost about 2.2% in that time frame, underperforming the market. Will the recent negative trend continue leading up to the stock’s …
The market starts on another down day as the Dog Days of August persist in whittling away the positive backdrop of the …